# A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

> **NCT04083976** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 316 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Erdafitinib

## Key facts

- **NCT ID:** NCT04083976
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-20
- **Primary completion:** 2023-12-04
- **Final completion:** 2026-02-28
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083976, "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04083976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*